BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 14561086)

  • 41. Discovery and characterization of triaminotriazine aniline amides as highly selective p38 kinase inhibitors.
    Lin TH; Metzger A; Diller DJ; Desai M; Henderson I; Ahmed G; Kimble EF; Quadros E; Webb ML
    J Pharmacol Exp Ther; 2006 Aug; 318(2):495-502. PubMed ID: 16702443
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation.
    Gill AL; Frederickson M; Cleasby A; Woodhead SJ; Carr MG; Woodhead AJ; Walker MT; Congreve MS; Devine LA; Tisi D; O'Reilly M; Seavers LC; Davis DJ; Curry J; Anthony R; Padova A; Murray CW; Carr RA; Jhoti H
    J Med Chem; 2005 Jan; 48(2):414-26. PubMed ID: 15658855
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Crystallization of MAP kinases.
    Lee SJ; Zhou T; Goldsmith EJ
    Methods; 2006 Nov; 40(3):224-33. PubMed ID: 16829129
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 3,5-Diphenylpent-2-enoic acids as allosteric activators of the protein kinase PDK1: structure-activity relationships and thermodynamic characterization of binding as paradigms for PIF-binding pocket-targeting compounds.
    Stroba A; Schaeffer F; Hindie V; Lopez-Garcia L; Adrian I; Fröhner W; Hartmann RW; Biondi RM; Engel M
    J Med Chem; 2009 Aug; 52(15):4683-93. PubMed ID: 19606904
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Improved expression, purification, and crystallization of p38alpha MAP kinase.
    Bukhtiyarova M; Northrop K; Chai X; Casper D; Karpusas M; Springman E
    Protein Expr Purif; 2004 Sep; 37(1):154-61. PubMed ID: 15294293
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitors.
    Hynes J; Dyckman AJ; Lin S; Wrobleski ST; Wu H; Gillooly KM; Kanner SB; Lonial H; Loo D; McIntyre KW; Pitt S; Shen DR; Shuster DJ; Yang X; Zhang R; Behnia K; Zhang H; Marathe PH; Doweyko AM; Tokarski JS; Sack JS; Pokross M; Kiefer SE; Newitt JA; Barrish JC; Dodd J; Schieven GL; Leftheris K
    J Med Chem; 2008 Jan; 51(1):4-16. PubMed ID: 18072718
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Thermodynamic characterization of allosteric glycogen phosphorylase inhibitors.
    Anderka O; Loenze P; Klabunde T; Dreyer MK; Defossa E; Wendt KU; Schmoll D
    Biochemistry; 2008 Apr; 47(16):4683-91. PubMed ID: 18373353
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Biphenyl amide p38 kinase inhibitors 2: Optimisation and SAR.
    Angell RM; Angell TD; Bamborough P; Brown D; Brown M; Buckton JB; Cockerill SG; Edwards CD; Jones KL; Longstaff T; Smee PA; Smith KJ; Somers DO; Walker AL; Willson M
    Bioorg Med Chem Lett; 2008 Jan; 18(1):324-8. PubMed ID: 17981461
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Structure-based identification of small molecule binding sites using a free energy model.
    Coleman RG; Salzberg AC; Cheng AC
    J Chem Inf Model; 2006; 46(6):2631-7. PubMed ID: 17125203
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The three-dimensional structure of MAP kinase p38beta: different features of the ATP-binding site in p38beta compared with p38alpha.
    Patel SB; Cameron PM; O'Keefe SJ; Frantz-Wattley B; Thompson J; O'Neill EA; Tennis T; Liu L; Becker JW; Scapin G
    Acta Crystallogr D Biol Crystallogr; 2009 Aug; 65(Pt 8):777-85. PubMed ID: 19622861
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Modeling of p38 mitogen-activated protein kinase inhibitors using the Catalyst HypoGen and k-nearest neighbor QSAR methods.
    Xiao Z; Varma S; Xiao YD; Tropsha A
    J Mol Graph Model; 2004 Oct; 23(2):129-38. PubMed ID: 15363455
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Quaternary structure of Dictyostelium discoideum nucleoside diphosphate kinase counteracts the tendency of monomers to form a molten globule.
    Cervoni L; Egistelli L; Mocan I; Giartosio A; Lascu I
    Biochemistry; 2003 Dec; 42(49):14599-605. PubMed ID: 14661972
    [TBL] [Abstract][Full Text] [Related]  

  • 53. N-Phenyl-N-purin-6-yl ureas: the design and synthesis of p38alpha MAP kinase inhibitors.
    Wan Z; Boehm JC; Bower MJ; Kassis S; Lee JC; Zhao B; Adams JL
    Bioorg Med Chem Lett; 2003 Mar; 13(6):1191-4. PubMed ID: 12643941
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Isoindolinone ureas: a novel class of KDR kinase inhibitors.
    Curtin ML; Frey RR; Heyman HR; Sarris KA; Steinman DH; Holmes JH; Bousquet PF; Cunha GA; Moskey MD; Ahmed AA; Pease LJ; Glaser KB; Stewart KD; Davidsen SK; Michaelides MR
    Bioorg Med Chem Lett; 2004 Sep; 14(17):4505-9. PubMed ID: 15357981
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Design and synthesis of potent pyridazine inhibitors of p38 MAP kinase.
    Tamayo N; Liao L; Goldberg M; Powers D; Tudor YY; Yu V; Wong LM; Henkle B; Middleton S; Syed R; Harvey T; Jang G; Hungate R; Dominguez C
    Bioorg Med Chem Lett; 2005 May; 15(9):2409-13. PubMed ID: 15837335
    [TBL] [Abstract][Full Text] [Related]  

  • 56. BREED: Generating novel inhibitors through hybridization of known ligands. Application to CDK2, p38, and HIV protease.
    Pierce AC; Rao G; Bemis GW
    J Med Chem; 2004 May; 47(11):2768-75. PubMed ID: 15139755
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A fragment-based approach for the discovery of isoform-specific p38alpha inhibitors.
    Chen J; Zhang Z; Stebbins JL; Zhang X; Hoffman R; Moore A; Pellecchia M
    ACS Chem Biol; 2007 May; 2(5):329-36. PubMed ID: 17465519
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Design and synthesis of piperazine-indole p38 alpha MAP kinase inhibitors with improved pharmacokinetic profiles.
    Tan X; Tester RW; Luedtke GR; Chakravarty S; Mavunkel BJ; Perumattam JJ; Lu Q; Nashashibi I; Jung J; Hu J; Liclican A; Almirez R; Tabora J; Tran V; Laney M; Levy DE; Dugar S
    Bioorg Med Chem Lett; 2010 Feb; 20(3):828-31. PubMed ID: 20071169
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The non-diaryl heterocycle classes of p38 MAP kinase inhibitors.
    Cirillo PF; Pargellis C; Regan J
    Curr Top Med Chem; 2002 Sep; 2(9):1021-35. PubMed ID: 12171569
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Thermodynamic stability of immunoglobulins and allosteric interactions with ferritin and protein A: distinct properties of the two antibodies of IgG2a subclass.
    Chumanevich AA; Kravchuk ZI; Vlasov AP; Zhorov OV; Martsev SP
    Biochemistry (Mosc); 1998 Apr; 63(4):476-84. PubMed ID: 9556532
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.